GlassScriptPhysician profile
Bradford Jones
NPI 1306912118
$5,479.27
in general payments reported to CMS, 2019-2025
35 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2020: $688 · 2021: $406 · 2022: $429 · 2023: $727 · 2024: $828 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,291.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $513.88 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $350.62 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.54 | 2019-2023 | Xifaxan |
| Pfizer INC. | $340.40 | 2019-2025 | |
| Janssen Biotech, INC. | $246.62 | 2019-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $146.13 | 2024 | Apollo Esg System |
| Celgene Corporation | $131.98 | 2022-2024 | Zeposia |
| Ucb, INC. | $120.58 | 2019-2020 | |
| Madrigal Pharmaceuticals | $109.01 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $88.50 | 2019-2021 | |
| Braintree Laboratories, INC. | $83.40 | 2019 | |
| Intercept Pharmaceuticals, INC. | $66.68 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $57.16 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $57.07 | 2019-2024 | Dificid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $52.51 | 2019 | |
| Endo Pharmaceuticals INC. | $51.76 | 2019-2020 | |
| Ardelyx, INC. | $48.01 | 2025 | Ibsrela |
| Medtronic, INC. | $45.67 | 2024 | Interstim |
| Qol Medical, LLC | $41.02 | 2024-2025 | Sucraid, Sucraid |
| Allergan, INC. | $40.48 | 2019 | |
| Nestle Healthcare Nutrition INC. | $28.86 | 2023 | |
| Intuitive Surgical, INC. | $21.98 | 2023 | Da Vinci Surgical System |
| Ipsen Biopharmaceuticals, INC | $20.91 | 2024 | Bylvay |
| Lucid Diagnostics INC. | $20.87 | 2025 | |
| Horizon Therapeutics Plc | $19.83 | 2019 | |
| Lilly USA, LLC | $19.40 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $19.22 | 2025 | Voquezna |
| Novo Nordisk INC | $18.73 | 2025 | Wegovy |
| Amgen INC. | $17.23 | 2022 | |
| Aimmune Therapeutics, INC. | $16.13 | 2024 | |
| Capsovision, INC. | $15.30 | 2023 | Capsocam Plus |
| Intra-Sana Laboratories | $13.59 | 2022 | |
| Shire North American Group INC | $11.92 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradford Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.